Shares Outstanding Shares Outstanding n/a Close	2.83M
Shares Change (YoY) Shares Change (YoY) n/a Close	-87.5%
Shares Change (QoQ) Shares Change (QoQ) n/a Close	0%
Owned by Institutions (%) Owned by Institutions (%) n/a Close	3.46%
Shares Floating Shares Floating n/a Close	16.41M
Failed to Deliver (FTD) Shares Failed to Deliver (FTD) Shares n/a Close	995
FTD / Avg. Volume FTD / Avg. Volume n/a Close	0.97%

Short Selling Information

The latest short interest is 55.57K, so 1.96% of the outstanding shares have been sold short.

Short Interest Short Interest n/a Close	55.57K
Short % of Shares Out Short % of Shares Out n/a Close	1.96%
Short % of Float Short % of Float n/a Close	2.11%
Short Ratio (days to cover) Short Ratio (days to cover) n/a Close	1

Valuation Ratios

The PE ratio is -1.55 and the forward PE ratio is null. ASLAN Pharmaceuticals's PEG ratio is 0.06.

PE Ratio PE Ratio n/a Close	-1.55
Forward PE Forward PE n/a Close	n/a
PS Ratio PS Ratio n/a Close	5.73
Forward PS Forward PS n/a Close	n/a
PB Ratio PB Ratio n/a Close	-5.17
P/FCF Ratio P/FCF Ratio n/a Close	-1.48
PEG Ratio PEG Ratio n/a Close	0.06

Financial Ratio History

Enterprise Valuation

ASLAN Pharmaceuticals has an Enterprise Value (EV) of 74.33M.

EV / Sales EV / Sales n/a Close	6.19
EV / EBITDA EV / EBITDA n/a Close	-1.71
EV / EBIT EV / EBIT n/a Close	-1.6
EV / FCF EV / FCF n/a Close	-1.6

Financial Position

The company has a current ratio of 1.84, with a Debt / Equity ratio of -2.02.

Current Ratio Current Ratio n/a Close	1.84
Quick Ratio Quick Ratio n/a Close	1.84
Debt / Equity Debt / Equity n/a Close	-2.02
Debt / EBITDA Debt / EBITDA n/a Close	-0.62
Debt / FCF Debt / FCF n/a Close	-0.58
Interest Coverage Interest Coverage n/a Close	-10.11

Financial Efficiency

Return on Equity is 332.81% and Return on Invested Capital is -324.03%.

Return on Equity Return on Equity n/a Close	332.81%
Return on Assets Return on Assets n/a Close	-179.56%
Return on Invested Capital Return on Invested Capital n/a Close	-324.03%
Revenue Per Employee Revenue Per Employee n/a Close	$342,857.14
Profits Per Employee Profits Per Employee n/a Close	$-1,263,417.26
Employee Count Employee Count n/a Close	35
Asset Turnover Asset Turnover n/a Close	0.49
Inventory Turnover Inventory Turnover n/a Close	n/a

Taxes

Income Tax Income Tax n/a Close	132.67K
Effective Tax Rate Effective Tax Rate n/a Close	-0.3%

Stock Price Statistics

The stock price has increased by -84.04% in the last 52 weeks. The beta is 1.4, so ASLAN Pharmaceuticals's price volatility has been higher than the market average.

Beta Beta n/a Close	1.4
52-Week Price Change 52-Week Price Change n/a Close	-84.04%
50-Day Moving Average 50-Day Moving Average n/a Close	1.78
200-Day Moving Average 200-Day Moving Average n/a Close	4.17
Relative Strength Index (RSI) Relative Strength Index (RSI) n/a Close	21.61
Average Volume (20 Days) Average Volume (20 Days) n/a Close	102,493

Income Statement

In the last 12 months, ASLAN Pharmaceuticals had revenue of 12M and earned -44.22M in profits. Earnings per share was -2.69.

Revenue Revenue n/a Close	12M
Gross Profit Gross Profit n/a Close	11.65M
Operating Income Operating Income n/a Close	-43.74M
Net Income Net Income n/a Close	-44.22M
EBITDA EBITDA n/a Close	-43.39M
EBIT EBIT n/a Close	-39.75M
Earnings Per Share (EPS) Earnings Per Share (EPS) n/a Close	-2.69

Full Income Statement

Balance Sheet

The company has 21.25M in cash and 26.83M in debt, giving a net cash position of -5.57M.

Cash & Cash Equivalents Cash & Cash Equivalents n/a Close	21.25M
Total Debt Total Debt n/a Close	26.83M
Net Cash Net Cash n/a Close	-5.57M
Retained Earnings Retained Earnings n/a Close	-321.07M
Total Assets Total Assets n/a Close	20.99M
Working Capital Working Capital n/a Close	972.05K

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -46.36M and capital expenditures -10.78K, giving a free cash flow of -46.37M.

Operating Cash Flow Operating Cash Flow n/a Close	-46.36M
Capital Expenditures Capital Expenditures n/a Close	-10.78K
Free Cash Flow Free Cash Flow n/a Close	-46.37M
FCF Per Share FCF Per Share n/a Close	-2.82

Full Cash Flow Statement

Margins

Gross margin is 97.1%, with operating and profit margins of -364.46% and -368.5%.

Gross Margin Gross Margin n/a Close	97.1%
Operating Margin Operating Margin n/a Close	-364.46%
Pretax Margin Pretax Margin n/a Close	-367.32%
Profit Margin Profit Margin n/a Close	-368.5%
EBITDA Margin EBITDA Margin n/a Close	-361.56%
EBIT Margin EBIT Margin n/a Close	-364.46%
FCF Margin FCF Margin n/a Close	-386.42%

Dividends & Yields

ASLN does not appear to pay any dividends at this time.

Dividend Per Share Dividend Per Share n/a Close	n/a
Dividend Yield Dividend Yield n/a Close	n/a
Dividend Growth (YoY) Dividend Growth (YoY) n/a Close	n/a
Payout Ratio Payout Ratio n/a Close	n/a
Earnings Yield Earnings Yield n/a Close	-64.31%
FCF Yield FCF Yield n/a Close	-67.44%

Dividend Details

Analyst Forecast

The average price target for ASLN is $72, which is 11900% higher than the current price. The consensus rating is "Buy".

Price Target Price Target n/a Close	$72
Price Target Difference Price Target Difference n/a Close	11900%
Analyst Consensus Analyst Consensus n/a Close	Buy
Analyst Count Analyst Count n/a Close	1

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value Lynch Fair Value n/a Close	n/a
Lynch Upside Lynch Upside n/a Close	n/a
Graham Number Graham Number n/a Close	n/a
Graham Upside Graham Upside n/a Close	n/a

Stock Splits

The last stock split was on Jul 3, 2024. It was a backward split with a ratio of 1:8.

Last Split Date Last Split Date n/a Close	Jul 3, 2024
Split Type Split Type n/a Close	backward
Split Ratio Split Ratio n/a Close	1:8

Scores

Altman Z-Score Altman Z-Score n/a Close	-26.87
Piotroski F-Score Piotroski F-Score n/a Close	3